1. Introduction

Massive cardiomyocyte death occurs during myocardial infarction resulting from acute ischemic attack [1]. Although emergency coronary recanilization restores blood supply to ischemic tissue, clinical and laboratory data often reveal sustained cardiac injury due to cardiomyocyte death within the first few minutes of reperfusion, a phenomenon known as ischemia-reperfusion (I/R) injury. The occurrence of I/R injury extends infarct area, which is a critical determinant of ventricular function and cardiovascular mortality [2]. Therefore, substantial efforts are being devoted to clarifying the pathogenic mechanisms of I/R injury to develop therapeutic approaches to minimize its consequences [3]. It is generally accepted that excessive death of cardiomyocyte is the fundamental pathological feature of myocardial I/R injury [4]. While the involvement of apoptosis in cardiomyocyte death is widely recognized, the occurrence of necroptosis, a distinct form of regulated cell death, has been highlighted by our previous studies [5,6] and other investigations [7,8]. Importantly,

**Corresponding author. Department of Cardiology, Chinese PLA General Hospital, Medical School of Chinese PLA, 28 Fuxing Road, Beijing, 100853, PR China.**

**Corresponding author. Department of Cardiology, Chinese PLA General Hospital, Medical School of Chinese PLA, 28 Fuxing Road, Beijing, 100853, PR China.**

E-mail addresses: tianfeng@126.com (F. Tian), zhouhao301@outlook.com, zhouhao@plagh.org (H. Zhou).

These authors contributed equally to this work.
pharmacological experiments and/or genetically-engineered mouse models of cardiac I/R injury have observed that ~30% of death is executed through apoptosis, whereas necroptosis accounts for ~50% of cardiomyocyte death during I/R episodes [7].

The fundamental mediators of necroptosis in cardiomyocytes include receptor-interacting protein kinase-3 (RIPK3), phosphoglycerate mutase 5 (PGAM5), and mixed lineage kinase domain-like pseudokinase (MLKL) [9,10]. RIPK3 acts as a sensor of environmental and cellular stress to initiate and transmit necroptotic signal to MLKL and PGAM5 [10]. MLKL, the principal RIPK3 substrate, acts as the terminal necroptosis executioner, triggering membrane rupture after phosphorylation at Ser358 [11,12]. PGAM5 is a serine/threonine-protein phosphatase –H. Zhu et al.–mediated inflammation response, PGAM5 expression is upregulated and promotes dynamin related protein-1 (Drp1) activation through Drp1<sup>6037</sup> dephosphorylation [14], an obligatory step for necroptosis induction. These observations were recently complemented by a study showing that cardiac PGAM5 expression in rats is upregulated by I/R injury and consequently induces Drp1<sup>6036</sup> phosphorylation and necroptosis activation [15]. By contrast, increased PGAM5 was shown to alleviate cardiomyocyte necroptosis by activating mitophagy in a mouse model of myocardial I/R injury [16]. Surprisingly, another study of mouse myocardial I/R injury reported a previously unforeseen role of PGAM5 in participation of apoptosis induction through the degradation of Bcl-xl [17]. In the present study, the cardiac-specific PGAM5 knockout mice were generated and used to clarify the regulatory roles and molecular mechanisms of PGAM5 in necroptosis and/or apoptosis (in)activation in the context of cardiac I/R injury.

A progressive disruption of mitochondrial function and structure is not only an adaptive response to reperfusion but also a critical process predisposing cardiomyocytes to apoptosis or necroptosis [18,19]. Under conditions of I/R injury, the mitochondrial quality control system is activated and principally devoted to restore mitochondrial homeostasis through the modification of mitochondrial redox reaction, fission, fusion, mitophagy, and bioenergetics. Superfluous ROS are produced at mitochondria correlating with cardiomyocyte oxidative stress at the stage of reperfusion [20]. In addition, mitochondrial fragmentation, caused by excessive mitochondrial fission, is not just a morphological adaptive response but also a contributor to mitochondrial membrane damage and consequent cell death [21,22]. Although mitochondrial fusion serves to counteract abnormal mitochondrial constriction and cleavage, its activity seems to be downregulated during the reperfusion phase [23]. As a mitochondria degradation system, mitophagy represents a double-edged sword for cardiomyocytes, as it can promote cell survival or trigger cell death depending on the physiopathogenic context [24]. Interestingly, cumulative evidence is emerging to support PGAM5 having diverse impacts on mitochondrial quality control. It is important to understand whether and how PGAM5 alters mitochondrial quality control participating in cardiac I/R injury. In the present study, we generated cardiac-specific PGAM5 knockout mice to attempt to clarify the molecular mechanisms underlying the regulatory roles of PGAM5 in mitochondrial bioenergetics, oxidative stress, fission, fusion, and mitophagy in cardiomyocytes enduring I/R injury.

2. Materials and methods

2.1. Experimental animals

All animal procedures were performed in accordance with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996) and approved by the Chinese PLA General Hospital and University of Wyoming Institutional Animal Use and Care Committees (Laramie, WY, USA). PGAM<sup>−/−</sup> mice were generated as previously described [6] and bred to α-MHC (alpha myosin heavy chain)<sup>Cre</sup> transgenic mice to generate cardiac-specific PGAM5 knockout (PGAM5<sup>Cre</sup>, PGAM5<sup>−/−</sup>, α-MHC<sup>Cre</sup>) mice. All genetically modified mice were crossed on a C57BL/6.N background for at least 10 generations. Male mice (8 weeks old) were used for in vivo experiments.

2.2. I/R surgery and infarct size assessment

I/R injury was conducted as previously described [25]. In brief, mice were anesthetized with 1%–3% isoflurane through inhalation (Baxter, USA). The left anterior descending (LAD) coronary artery was temporarily ligated for 45 min, followed by 0–24 h reperfusion. Sham operation was performed by opening the chest and exposing the pericardium of anesthetized mice, leaving the LAD intact. For each experimental condition, a minimum of 6 mice were examined. After reperfusion, 2% Evans blue/saline were injected into mice to demarcate the ischemic area at risk (AAR). Then, the hearts were excised and cut into five 1-mm slices, which were incubated with 1% 2,3,5-triphenyltetrazolium chloride (TTC) for 10 min at 37 °C to demonstrate infarct size (IS). The percentage of IS and AAR of individual myocardial sections was multiplied by the corresponding section weight. To inhibit apoptosis or necroptosis, mice were intraperitoneally injected with a mitophagy activator (Urolithin A, Sigma, USA, No. SML1791, 10 mg/kg) or antagonist (MF-094, Sigma, No. SML2501, 20 mg/kg) 12 h before I/R injury. To activate or inhibit mitophagy, mice were intraperitoneally injected with a mitophagy activator (Urolithin A, Sigma, USA, No. SML1791, 10 mg/kg) or antagonist (MF-094, Sigma, No. SML2501, 20 mg/kg) 12 h before I/R injury.

2.3. Echocardiography and electron microscopy

Echocardiography was performed in mice after I/R surgery using a Vevo 2100 system (FUJIFILM VisualSonics, Canada) as our previously described [25]. For electron microscopy, heart tissue fragments were excised from the left ventricle and washed with 0.1 M sodium cacodylate, post-fixed in 1% OsO<sub>4</sub> for 1 h, dehydrated in graded acetone, and embedded in Epon-Araldite resin. Thin (80 nm) and semi-thick (280 nm) sections were placed on formvar-coated slot-grids and post stained with 2% aqueous uranyl acetate and Reynold’s lead citrate. Colloidal gold particles (15 nm) were added to both surfaces of the semi-thick sections to serve as fiducial markers for tilt-series alignment. Preparations were imaged at the EMBL Heidelberg Electron Microscopy Core Facility using a Tecnai F30 electron microscope operating at 300 kV and a Phillips CM120 BioTwin electron microscope operating at 120 kV. Images were captured on a 4K Eagle camera and a SIS 1K KeenView device.

2.4. Cell culture and sl/r injury in vitro

Primary cardiomyocytes were isolated from wild-type (WT), PGAM<sup>−/−</sup>, and PGAM<sup>Cre</sup> mice and cultured for 24–48 h in DMEM (Gibco, ThermoFisher, USA) supplemented with 1% -glutamine, 20% fetal bovine serum (FBS), and 1% penicillin-streptomycin. Simulated I/R (sl/R) injury was induced in vitro through 45-min hypoxia and 4-h reoxegenation according to our previous protocols [24,25]. To inhibit apoptosis or necroptosis, cell-permeable Z-VAD-FMK (20 μM) and Necrostatin-1 (Selleck Chemicals; No. S8037, 5 mg/kg) were added to cultured cardiomyocytes before I/R injury. To activate or inhibit mitophagy, cardiomyocytes were treated with Urolithin A (20 μM) or MF-094 (5 mM) for 6 h before sl/R injury.

2.5. Cardiomyocyte contraction measurements

After reperfusion, ventricular cardiomyocytes were isolated from PGAM<sup>−/−</sup> and PGAM<sup>Cre</sup> mice via Langendorff perfusion [24] and...
allowed to settle in a pacing chamber for 5 min prior to the initiation of laminar flow from an in-line solution heater set to 37 °C. Cell contraction was measured by bright-field microscopy with external field pacing at 1 Hz using the IonWizard acquisition system (IonOptix Corp., USA). Contraction parameters were automatically quantified and averaged over at least 10 contractions for each cell. Cells from 2 to 3 mice were isolated for each condition.

2.6. Immunoprecipitation analysis

Co-immunoprecipitation (Co-IP) was conducted using a magnetic IP kit (Thermo Fisher Scientific, USA). In short, protein lysates from cardiomyocytes (1000 μg total protein) were incubated with 10 μg of anti-Drp1 monoclonal antibody overnight at 4 °C [26]. Immune complexes were bound to protein A/G magnetic beads and collected with a magnetic stand. Proteins co-immunoprecipitated with Drp1 were eluted and subjected to gel electrophoresis and immunoblotting using the antibodies described in Supplemental Table 1. Normal IgG was used as a negative IP control [27].

2.7. Immunofluorescence and TUNEL

The samples (cardiomyocytes or reperfused heart tissues) were fixed in ice-cold fixative (4% paraformaldehyde and 0.5% glutaraldehyde in PBS) for 18 min in the dark at room temperature, followed by permeabilization for 4 min with 0.2% Triton X-100 in PBS [28]. The samples were subsequently incubated with primary antibodies at 4 °C in a humidified chamber, washed in PBS, and incubated with secondary antibodies (1:500 dilution in blocking buffer) for 1 h at room temperature or overnight at 4 °C in a humidified chamber. After three washes in PBS, coverslips were mounted on slides with a Vectashield mounting medium containing DAPI (Vector Laboratories, USA; No. H-1200) [29]. Images were obtained using a Zeiss fluorescence microscope. The antibodies used for immunofluorescence are listed in the Supplemental Table 1. For TUNEL assays, tissue slides and cells were reacted with terminal deoxynucleotidyl transferase (TdT) enzyme and fluorescently-labeled 3'-phosphate (dUTP) at 37 °C for 1 h. The nuclei were stained with DAPI. The number of TUNEL-positive cells was determined from fluorescence microscopy images [30].

2.8. LDH cytotoxicity assay, MTT assay, and caspase-3 activity assay

Cell death was determined through LDH release assay. An LDH Cytotoxicity Assay Kit (Beyotime, China; No: C0016) was used to measure the levels of LDH released by necrotic cardiomyocytes according to the manufacturer’s manual [31]. The MTT assay was used to analyze cardiomyocyte viability. Briefly, cardiomyocytes (10^5/well) were seeded into 96-well plates and were subjected to sI/R injury 24 h later. Afterwards, the MTT assay was performed and cell viability examined by measuring wells’ absorbance at 490 nm on a microplate reader (Synergy™ 2; BioTek Instruments, Inc., USA) [32]. Caspase-3 activity was determined through an ELISA kit (Beyotime, China, Cat. No:C1115) according to the manufacturer’s manual [33].

2.9. Real time PCR

Heart tissue and cultured cardiomyocytes were homogenized in RLT buffer, and RNA was extracted using an RNeasy mini kit (Qiagen, USA; No. 74104). The extracted RNA was reverse transcribed into cDNA using a high-capacity cDNA reverse transcription kit (Applied Biosystems, Lithuania; No. 4368814). Quantitative real-time PCR was performed using a Power SYBR Green PCR Master Mix (Applied Biosystems, UK; No. 4368708) on an Applied Biosystems ABI Prism machine [34]. Amplification conditions consisted of one cycle at 50 °C for 2 min and one cycle at 95 °C for 10 min, followed by 40 cycles at 95 °C for 15 s and at 60 °C for 1 min. Fold-change gene expression was determined using cycle threshold (Ct) values and normalized to GAPDH expression [35]. The primers are listed in the Supplemental Table 2.

2.10. Immunoblot analysis

Cells and cardiac tissues were homogenized using 1 x Cell Lysis Buffer (Cell Signaling Technology, USA) supplemented with protease inhibitor cocktail and phosphatase inhibitors (Thermo Fisher Scientific, USA) and centrifuged at 4 °C for 10 min at 10,000 x g [36]. The resulting supernatant was mixed with a 5x protein loading buffer. The protein lysates were boiled at 60 °C for 5 min, and the protein contents were determined using a BCA assay. Aliquots of 15–30 μg protein per sample were fractionated on 10% SDS-PAGE gels, transferred onto PVDF membranes, and blocked in blocking buffer (PBS with 5% BSA, 0.1% Tween 20). Membranes were incubated with primary antibodies overnight at 4 °C, extensively washed, and incubated with HRP-conjugated anti-mouse or anti-rabbit whole IgG secondary antibodies (1:5000, Thermo Fisher Scientific) for 1 h at room temperature. Western Bright ECL HRP substrate (Advanza, USA) was then applied, and protein bands were detected using a ChemiDoc MP system (BioRad Laboratories, USA) [37]. Protein band intensity quantification analysis was performed with ImageLab software version 5.1. The antibodies that were used for western blots are listed in the Supplemental Table 1.

2.11. Mitochondrial ROS and membrane potential measurements

Mitochondrial ROS production was determined using the MitosOX red mitochondrial superoxide indicator (Thermo Fisher Scientific; No. M36008) according to the manufacturer’s instructions [38,39]. In brief, cardiomyocytes were washed with warm PBS, loaded with 2 μmol/L MitosOX red at 37 °C for 30 min, and washed with warm PBS again. Then, fluorescence (excitation 485 nm, emission 535 nm) was measured in a microplate reader. Representative photomicrographs of MitosOX stained cells were taken using a Zeiss Axio Imager M1 fluorescence microscope (Carl Zeiss, Germany). Mitochondrial membrane potential was detected through a Mitochondrial Membrane Potential JC-1 Kit (Beyotime, China, No. C2006) [40,41]. In brief, the cardiomyocytes were washed with warm PBS and then loaded with 2.5 mg/ml JC-1 for 30 min at 37 °C. After DAPI staining, the fluorescent images were analyzed under a Zeiss Axio Imager M1 fluorescence microscope (Carl Zeiss, Oberkochen, Germany) [42,43]. Mitochondrial potential is expressed as relative aggregate-to-monomer (red/green) fluorescence intensity ratio.

ATP detection, mPTP opening rate measurement, and mitochondrion assay.

Total ATP production was measured through an ATP Assay Kit (Abcam, UK; No. ab83355) [44,45]. In brief, cardiomyocytes were harvested, washed with PBS, and then resuspended in 100 μL of ATP assay buffer. Cells were homogenized and then centrifuged (4 °C at 13,000 g) to remove any insoluble material. The supernatants were then collected and incubated with the ATP probe. Absorbance was detected at 580 nm using a microplate reader (Epoch 2; BioTek Instruments, Inc.). The results are presented as the ratio between the test and control values [46].

The mPTP opening rate was determined by loading cardiomyocytes with 5 μmol/L Calcein-AM (Molecular Probes, USA) and 2–5 mmol/L cobalt chloride. The results are presented as fluorescence intensity relative to control [5]. The fluorescent, pH-sensitive mitochondrion reporter Keima (pMT-mKeima-Red, MBL Medical & Biological Laboratories, USA; No. AM-V-251) has a bimodal excitation spectra defined by a 440 nm peak at neutral pH and a 568 nm peak under acidic pH conditions. The Keima-Red plasmid was transfected into cardiomyocytes according to the manufacturer’s instructions. Mitophagy was quantified as the 550 nm/440 nm excitation ratio [47,48].
2.12. Gene silencing and overexpression

Adenoviral (Ad) vectors containing the PGAM5 gene (Ad-PGAM5) and control adenovirus carrying the β-galactosidase (β-gal) reporter gene (Ad-β-gal) were constructed as previously described [6]. Briefly, Myc-tagged WT PGAM5 cDNA was sub-cloned into a pcDNA3 vector, followed by adenovirus generation. Viral particles were quantified using an Adeno-X-Rapid Titer Kit (Clontech, USA). A multiplicity of infection (MOI) of 100 was used to transduce Ad-PGAM5 into cardiomyocytes [49]. The transduction efficiency was verified by both Western blot and direct observation using fluorescence microscopy. shRNAs against CK2 and PGAM5 were purchased from GenePharma (Shanghai, China). Cell transfection was performed using Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer’s protocol.

2.13. Statistical analysis

Data are presented as the mean ± SEM of at least three independent experiments. After confirming by the Kolmogorov-Smirnov test followed by Q-Q plots analysis that all variables were normally distributed, statistical differences were determined by Student’s t-test for comparison between two groups and ANOVA followed by Bonferroni’s multiple comparison test for comparison among three or more groups. P < 0.05 was considered significant. Statistical calculations were carried out using GraphPad Prism 6.0 or SPSS version 17.0.

3. Results

3.1. PGAM5 promotes I/R-mediated cardiomyocytes necroptosis

To characterize the effect of I/R on cardiomyocyte PGAM5 levels, we first isolated mouse primary cardiomyocytes and subjected them to simulated I/R (sl/I/R). Relative to the baseline, PGAM5 transcription (Supplemental Fig. 1A) and protein expression (Supplemental Fig. 1B–D) increased following sl/I/R injury. This effect was paralleled by an elevation in phospho-MLKl expression (Supplemental Fig. 1B–D). In vivo, cardiac PGAM5 mRNA (Fig. 1A) and protein levels (Fig. 1B–D) started to increase following I/R injury in a time-dependent manner, plateaued at 4-h reperfusion, and decreased in subsequent hours, returning to the baseline at 16-h reperfusion. Similar results were also observed in the expression of phospho-MLKL (Fig. 1B–D). Thus, 45-min ischemia and 4-h reperfusion were selected to explore the role of PGAM5 in I/R-mediated cardiac damage.

What is the biologic function within cells of increased PGAM5 in cardiac I/R injury? Previous research showed an important regulatory role for PGAM5 in cell death mediated by apoptosis or necroptosis [13, 50]. To test whether PGAM5 participates in apoptosis and/or necroptosis activation in the reperfused heart, the cardiac-specific PGAM5 deletion mice (PGAM5−/−) were generated, and primary cardiomyocytes were isolated from WT and PGAM5−/− mice and their corresponding PGAM5+/ mice. Cell death index, as assessed through LDH release assay (Fig. 1E) and MTT assay (Fig. 1F), was elevated in PGAM5−/− cardiomyocytes and markedly lower in PGAM5+/ cardiomyocytes after sl/I/R injury. To access whether PGAM5 regulates cardiomyocyte apoptosis and/or necroptosis induced by I/R injury, cardiomyocytes were treated with the apoptosis inhibitor Z-VAD-FMK and the necroptosis blocker Necrostatin-1 (Nec-1). Then, TUNEL and caspase-3 double-immunofluorescence assay was applied to observe apoptosis and necroptosis. After sl/I/R injury, ~18% PGAM5−/− cardiomyocytes were TUNEL+/Caspase-3− (apoptotic marker), while ~27% PGAM5+/ cardiomyocytes were TUNEL+/Caspase-3− (necroptosis index) (Fig. 1G–I). This suggests that both apoptosis and necroptosis are activated by reperfusion damage. In sl/I/R-treated PGAM5+/ cardiomyocytes, only ~4% of cells were TUNEL+/Caspase-3−, whereas the ratio of TUNEL+/Caspase-3− apoptotic cells was unchanged (~18%) (Fig. 1G–I), suggesting that necroptosis rather than apoptosis was interrupted by PGAM5 deletion. Interestingly, supplementation with Z-VAD-FMK further reduced the ratio of PGAM5+/ TUNEL+/Caspase-3− cardiomyocytes to ~3%; this reduction was akin to that observed in PGAM5−/− cardiomyocytes co-administered with Z-VAD-FMK and Nec-1 (Fig. 1G–I). These data highlight that the inhibition of apoptosis further represses the sl/I/R-induced death of PGAM5+/ cardiomyocytes, which suggests that PGAM5 controls necroptosis rather than apoptosis upon cardiac I/R injury. To substantiate these findings, we analyzed the cardiac expression of apoptosis- and necroptosis-related proteins after I/R in vivo. Relative to the sham-operated control mice, the levels of pro-apoptotic proteins (caspase-3, caspase-9, Bax/Bcl2) and pro-necrotic markers (phospho-MLKL) were markedly increased in I/R-treated PGAM5−/− hearts (Fig. 1J–O). By comparison, the expression of phospho-MLKL, but not of pro-apoptotic proteins, was lower in the hearts of PGAM5+/ mice following I/R injury (Fig. 1J–O).

To evaluate whether PGAM5 upregulation is sufficient to induce cardiomyocyte necroptosis under non-stress conditions, adenovirus-mediated PGAM5 overexpression (Ad-PGAM5) was established in cardiomyocytes isolated from wild-type (WT) mice (Supplemental Fig. 2A and B). Compared to control (Ad-β-gal-transduced) cells, higher LDH release was detected in Ad-PGAM5-transduced cardiomyocytes (Supplemental Fig. 2C). Besides, increased PGAM5 expression was correlated with a rise in the ratio of TUNEL+/Caspase-3− necroptotic cardiomyocytes (Supplemental Fig. 2D–F), underscoring the fact that cardiomyocytes with elevated PGAM5 expression have a pronounced susceptibility to necroptosis in a physiological context. Overall, necroptosis rather than apoptosis is induced by PGAM5 in cardiac I/R injury.

PGAM5 does not trigger mitophagy-related cardiomyocyte death in the reperfused heart.

In addition to apoptosis or necroptosis, PGAM5 has also been shown to positively regulate mitophagic cell death (or mitophagy-related cell death) [51], a newly identified cell death program reported to be a key event in the pathogenesis of cardiovascular disorders [52]. Although mitochondrial autophagy was found to be suppressed at the stage of reperfusion [53,54], it is unclear whether PGAM5 expression influences mitophagic cell death during cardiac I/R injury. To address this, PI staining was conducted to evaluate necroptosis-related cell membrane rupture in primary mouse cardiomyocytes treated with a mitophagy activator (Urolithin A) or a mitophagy antagonist (MF-094) under sl/I/R injury. First, compared to sl/I/R-treated cardiomyocytes, administration of MF-094 showed no impact on the ratio of PI− necrotic cells in either PGAM5+/ or PGAM5−/− cardiomyocytes (Fig. 2A–B), supporting that cardiomyocytes die independently of mitophagy and that PGAM5 has no association with mitophagy-related cell death. By comparison, following a sl/I/R challenge, significantly fewer PGAM5+/ or PGAM5−/− cardiomyocytes were PI− after Urolithin A exposure (Fig. 2A–B). These data might indicate that mitophagy activation provides a pro-survival signal in the reperfused heart. In addition to necroptotic marker PI staining, caspase-3 activity, an apoptotic parameter, was increased by sl/I/R injury but reduced to near-normal levels by prior exposure to Urolithin A (Fig. 2C). By contrast, MF-094 supplementation had no influence on sl/I/R-mediated caspase-3 activation in either PGAM5+/ or PGAM5−/− cardiomyocytes (Fig. 2C). With the help of TUNEL and Caspase-3 double immunofluorescence assay, we also observed that MF-094 treatment had no influence on sl/I/R-induced cardiomyocytes apoptosis (TUNEL+/Caspase-3−) or necroptosis (TUNEL+/Caspase-3−) (Fig. 2D–F). In contrast, supplementation of Urolithin A was associated with the repression of both necroptosis and apoptosis in sl/I/R-treated cardiomyocytes (Fig. 2D–F).

In line with the findings in vitro, administration of MF-094 prior to I/R injury in vivo did not affect the expression of pro-apoptotic proteins or necroptosis-related factors in either PGAM5+/ or PGAM5−/− hearts (Fig. 2G–I). However, pre-treatment of Urolithin A to activate mitophagy significantly reduced the levels of pro-apoptotic proteins and...
Fig. 1. PGAM5 upregulation promotes cardiomyocyte necroptosis after I/R injury. (A) Evaluation of cardiac PGAM5 expression through qPCR in mice subjected to I/R surgery. (B) Western blot detection of cardiac PGAM5 and phospho-MLKL expression following I/R injury. (C–D) Quantitative analysis of PGAM5 and phospho-MLKL levels in heart samples processed for western blotting. (E) Evaluation of cardiomyocyte necrosis through the LDH release assay. (F) MTT assay was used to evaluate cell death. (G–I) Representative images of TUNEL and caspase-3 double immunofluorescence in PGAM5+/f and PGAM5−/− cardiomyocytes. The apoptosis inhibitor Z-VAD-FMK and the necroptosis blocker Necrostatin-1 were applied to isolated cardiomyocytes before sI/R injury. (J–O) Western blot detection of apoptosis- and necroptosis-related proteins in heart extracts from PGAM5+/f and PGAM5−/− mice subjected to I/R injury. Before I/R injury, the mice were injected with the apoptosis inhibitor Z-VAD-FMK or the necroptosis blocker Necrostatin-1. Experiments were repeated three times with similar results. Data are shown as the means ± SEM, n = 6 mice or 3 independent cell isolations per group. *p < 0.05.

Fig. 2. Mitophagy-related cell death is absent in the reperfused heart. (A–B) Representative PI staining images from PGAM5+/f and PGAM5−/− cardiomyocytes treated with either Urolithin A or MF-094 and exposed to sI/R injury. (C) Caspase-3 activity assay results. (D–F) Representative images of TUNEL and caspase-3 double immunofluorescence in PGAM5+/f and PGAM5−/− cardiomyocytes treated with Urolithin A or MF-094 prior to I/R surgery. (G–L) Western blot detection of apoptosis- and necroptosis-related markers in cardiac samples from PGAM5+/f and PGAM5−/− mice treated with Urolithin A or MF-094 prior to I/R surgery. Experiments were repeated three times with similar results. Data are shown as the means ± SEM, n = 6 mice or 3 independent cell isolations per group. *p < 0.05.
necroptosis-related factors in PGAM5f/f and PGAM5CKO hearts (Fig. 2G-L). These data indicate that I/R-mediated PGAM5 upregulation does not promote mitophagy-related cell death in cardiomyocytes, and otherwise suggest that mitophagy has a pro-survival effect in the reperfused heart.

3.2. Cardiac-specific PGAM5 deletion reduces myocardial infarction area and attenuates cardiac inflammation

Compared to PGAM5f/f mice, PGAM5CKO mice exhibited decreased myocardial infarction area after I/R injury (Fig. 3A–C). Serum concentrations of myocardial damage indicators such as LDH, troponin T, and CK-MB were not significantly different between untreated PGAM5f/f and PGAM5CKO mice, but increased significantly, compared to the latter, in PGAM5f/f mice following I/R (Fig. 3D–F). Consistently, histopathological evidence obtained through electron microscopy showed mitochondrial swelling, cardiomyocyte destruction, and Z-line disappearance in heart tissue from PGAM5f/f mice (Fig. 3G). By comparison, improved myocardial structure and mitochondrial morphology following I/R injury was observed in PGAM5CKO mice (Fig. 3G).

We next applied qPCR to analyze the expression of pro-inflammatory factors in reperfused heart tissues. The results showed that I/R induced significant upregulation of IL-6 and MCP1 expression in cardiac samples from PGAM5f/f mice, whereas this effect was attenuated in PGAM5CKO mice (Fig. 3H–I), possibly due to a reduction in cardiomyocyte necroptosis after genetic ablation of PGAM5. Under non-stress conditions, the transcription of IL-6 and MCP1 was drastically upregulated in cardiomyocytes transfected with Ad-PGAM5 compared to those transfected with the control Ad-β-gal (Supplemental Fig. 3A and B).

3.3. Genetic ablation of PGAM5 sustains myocardial function upon I/R injury

To investigate whether PGAM5 deletion affects cardiac function, we performed echocardiography in PGAM5f/f and PGAM5CKO mice. PGAM5 deletion had no impact on baseline myocardial performance but attenuated I/R-mediated cardiac depression (Fig. 4A–C).
the mechanical properties of single cardiomyocytes acutely isolated from I/R-treated mice. Compared to cells from sham-operated mice, resting cardiomyocyte length was not influenced by I/R (Fig. 4D–I). However, the cardiomyocytes from I/R-treated PGAM5^{ff} mice presented obviously decreased PS and ±dL/dt as well as prolonged TPS and TR90, whereas these alterations were normalized in the cardiomyocytes isolated from PGAM5^{CKO} mice (Fig. 4D–I). In turn, under non-stress conditions, decreased PS and ±dL/dt and extended TPS and TR90 were detected after the transfection of Ad-PGAM5 into primary cardiomyocytes isolated from WT mice (Supplementary Fig. 4A–F). These data suggest that PGAM5 expression compromises myocardial function through impairing cardiomyocyte contractile/relaxation properties.

3.4. PGAM5 deletion improves cardiomyocyte mitochondrial function

Mitochondrial quality control has emerged as a critical cardioprotective target in the setting of I/R-mediated myocardial damage [20,55,56]. Interestingly, the mechanisms responsible for mitochondrial quality control have been shown to be finely tuned by PGAM5 through pleiotropic mechanisms involving mitochondrial oxidative stress [57], mitochondrial dynamics [14], and mitophagy [58–60]. These findings prompted us to investigate the interdependency of PGAM5 and mitochondrial function in I/R-mediated cardiomyocyte damage. Mitochondrial membrane potential, an index of mitochondrial bioenergetics, was dissipated by sI/R in PGAM5^{ff} but not in PGAM5^{CKO} cardiomyocytes (Fig. 5A–B). Consistently, cellular ATP production was significantly repressed by sI/R injury but enhanced instead after PGAM5 depletion (Fig. 5C). Interestingly, we observed that the activities of mitochondrial electron transport chain complexes (ETCx), including Cox-I, Cox-II, and Cox-V, were drastically down-regulated following sI/R injury in PGAM5^{ff} but not in PGAM5^{CKO} cardiomyocytes (Fig. 5D–F). Several ETCx components are encoded by mitochondrial DNA (mtDNA). In our study, both mtDNA copy number (Fig. 5G) and mtDNA-specific transcript expression (Fig. 5H) were
decreased in sI/R-treated PGAM5\textsuperscript{f/f} cardiomyocytes, an effect paralleled by a decrease in state-3/4 respiration (Fig. 5I–J). In turn, sI/R-treated PGAM5\textsuperscript{CKO} cardiomyocytes showed partial but significant preservation of mtDNA copy number and transcript levels (Fig. 5G–H) as well as improved state-3/4 respiration (Fig. 5I–J). Moreover, due to blunted mitochondrial bioenergetics, mitochondrial ROS (mtROS), a byproduct of mitochondrial respiration, was significantly increased by sI/R injury in PGAM5\textsuperscript{f/f} cardiomyocytes but was maintained at normal levels after the deletion of PGAM5 (Fig. 5K–L). In addition, following sI/R, the opening of the mitochondrial permeability transition pore (mPTP), an event predictive of mitochondria-regulated necroptosis [7, 61], was apparently augmented in PGAM5\textsuperscript{f/f} cardiomyocytes but unaffected in PGAM5\textsuperscript{CKO} cardiomyocytes (Fig. 5M). On the other hand, under non-stress conditions, cardiomyocytes transfected with Ad-PGAM5 exhibited lower mitochondrial potential (Supplemental Fig. 5A and B), increased mtROS generation (Supplemental Fig. 5C and D), and augmented mPTP opening rate (Supplemental Fig. 5E). Therefore, these data support the functional importance of PGAM5 in managing cardiomyocytes mitochondrial homeostasis.

### 3.5. PGAM5 deletion normalizes mitochondrial dynamics by suppressing Drp1\textsuperscript{Ser637} dephosphorylation

To complement the above observations on mitochondrial bioenergetics and oxidative stress, we monitored whether PGAM5 expression would also affect mitochondrial morphology in cardiomyocytes. As
shown in Fig. 6A–C, sI/R injury resulted in mitochondrial fragmentation denoted by organelle cleavage into small spheres or short rods. This effect was counteracted by PGAM5 depletion, which clearly restricted mitochondrial fragmentation after sI/R (Fig. 6A–C). Under non-stress conditions, shorter mitochondria were observed in PGAM5-overexpressing cardiomyocytes compared to control cells (Supplemental Fig. 6A–C). Furthermore, electron microscopy (EM) confirmed the presence of mitochondrial swelling, disorganized cristae, and fragmented, shorter mitochondria in I/R-treated PGAM5f/+ heart tissue. In contrast, these alterations were largely absent in heart samples from I/R-treated PGAM5CKO mice (Fig. 6D).

PGAM5 was initially discovered as a factor promoting mitochondrial fission through dephosphorylation of Drp1[S637] [14]. Evidence suggests that either Drp1[S616] phosphorylation or Drp1[S637] dephosphorylation promotes Drp1 oligomerization and subsequently drives mitochondria constriction and cleavage [62]. In our study, myocardial Drp1[S637] dephosphorylation was enhanced by I/R stimulus, whereas this conformational switch was attenuated by PGAM5 deletion (Fig. 6E–G). Under non-stress conditions, PGAM5 overexpression induced Drp1[S637] dephosphorylation (Supplemental Fig. 6D–F). Unlike Drp1[S637], PGAM5 deletion did not affect I/R-mediated Drp1[S616] phosphorylation (Fig. 6E–G). Similar observations were also noted in cardiomyocytes transfected with Ad-PGAM5 under non-stress conditions (Supplemental Fig. 6D–F). Mechanistically, PGAM5 is a serine/threonine-protein phosphatase, and the crosslink between PGAM5 and Drp1 was predicted theoretically to induce Drp1 dephosphorylation [14]. Endogenous interaction between PGAM5 and Drp1 was confirmed in I/R-treated hearts through co-immunoprecipitation assays (Fig. 6H). Consistently, endogenous PGAM5 was pulled down by Drp1 in cardiomyocytes cultured under non-stress conditions (Supplemental Fig. 6G). These data indicate that PGAM5 acts as an upstream mediator of Drp1[S637] dephosphorylation to promote I/R-mediated mitochondrial fission.
Pathological mitochondrial fragmentation may be a combined result of activated fission and suppressed fusion [63]. It remains unclear whether mitochondrial fusion is also influenced by PGAM5. To address this possibility, we compared the expression of mitochondrial fusion-related proteins in PGAM5<sup>f/f</sup> and PGAM5<sup>CKO</sup> mice following I/R injury. As shown in Fig. 6I–K, a slight decline in Mfn2 and OPA1 levels occurred in I/R-treated PGAM5<sup>f/f</sup> cardiomyocytes; however, these proteins maintained baseline expression levels in I/R-treated PGAM5<sup>CKO</sup> cardiomyocytes. Thus, these data provide preliminary evidence for a regulatory role of PGAM5 in sustaining mitochondrial fusion.

3.6. PGAM5 had no impact on impaired mitophagy in I/R-treated heart

In addition to mitochondrial dynamic, mitophagy eliminates damaged mitochondria and protects the heart against various types of stresses. FUN14 domain-containing protein 1 (Fundc1)-induced mitophagy can be inactivated by casein kinase 2 (CK2)-mediated phosphorylation of Fundc1<sup>S13</sup>, but it is then reactivated by PGAM5-mediated Fundc1<sup>S13</sup> dephosphorylation under hypoxic stimulation [60]. These observations prompted us to investigate the potential role of PGAM5 on mitophagy during cardiac I/R. Western blot analysis demonstrated that Fundc1<sup>S13</sup> dephosphorylation (i.e., active status) was drastically attenuated by I/R injury, but PGAM5 depletion did not rescue this effect (Fig. 7A). This suggests that mitophagy was impaired by reperfusion injury independently of PGAM5. Interestingly, CK2 knockdown increased Fundc1<sup>S13</sup> dephosphorylation in I/R-treated cardiomyocytes (Fig. 7B), suggesting that CK2 deletion activates Fundc1. In turn, PGAM5 depletion substantially suppressed the increase in Fundc1<sup>S13</sup> dephosphorylation observed in CK2 knockdown cardiomyocytes after I/R (Fig. 7B). These data indicate that Fundc1 dephosphorylation and activation are prevented by CK2, but enabled by PGAM5 under CK2-deficient conditions. This finding was further validated in cardiomyocytes cultured under non-stress conditions, in which PGAM5 overexpression failed to alter Fundc1<sup>S13</sup> phosphorylation levels relative to baseline (Supplemental Fig. 7A and B). By comparison, CK2 deletion induced Fundc1<sup>S13</sup> dephosphorylation, suggesting that baseline Fundc1 activity is repressed by CK2 (Supplemental Fig. 7C). Further, in CK2 knockdown cardiomyocytes, PGAM5

---

Fig. 7. PGAM5 deletion does not alter impaired mitophagy in I/R-treated hearts. (A) proteins were isolated from reperfused heart tissues and then the expression of p-Fundc1<sup>S13</sup> expression was detected through western blots. (B) Western blot analysis of p-Fundc1<sup>S13</sup> expression in sI/R-treated, WT cardiomyocytes previously transfected with shRNAs against CK2 or PGAM5. (C–D) The mt-Kemia reporter assay was performed in sI/R-exposed cardiomyocytes to detect mitophagic activity in response to PGAM5 deletion. (E–F) Representative images of double-immunofluorescence for mitochondrial (Tom20) and lysosomal (Lamp1) markers. (G–I) Western blot analysis of LC3II/I and p62 expression in PGAM5<sup>f/f</sup> and PGAM5<sup>CKO</sup> mice subjected to I/R injury. Experiments were repeated three times with similar results. Data are shown as the means ± SEM, n = 6 mice or 3 independent cell isolations per group. *p < 0.05.
deficiency attenuated (Fig. 7B) while PGAM5 overexpression augmented (Supplemental Fig. 7C) Fundc1\textsuperscript{S616} dephosphorylation. These results suggest that Fundc1 activation is mainly and negatively governed by CK2, whereas PGAM5 functions to restore Fundc1 activation in the absence of CK2.

In light of the necessary role of Fundc1 as a mitophagy inducer, the pH-sensitive, mitochondria-targeted mt-Kemia probe was used to detect mitophagic activity in response to PGAM5 deletion under cardiac I/R injury. At the baseline, several acidic mitochondria (or lysosome-mitochondria) complexes were detected in isolated cardiomyocytes (Fig. 7C–D). After exposure to sI/R, the number of acidic complexes was reduced regardless of PGAM5 expression levels (Fig. 7C–D). Indeed, neither Ad-PGAM5 nor Ad-β-gal transfection affected basal mitophagy in cultured cardiomyocytes under non-stress conditions (Supplemental Fig. 7D and E). The formation of lysosome-mitochondria complexes was further validated through double-immunofluorescence for Lamp-1 (lysosome marker) and Tom20 (mitochondrial marker). In untreated cardiomyocytes, normal, filamentous mitochondria appeared partly engulfed by lysosomes, indicative of moderate mitophagy at baseline (Fig. 7E–F). Upon sI/R injury, PGAM5\textsuperscript{-/} cardiomyocytes exhibited fragmented mitochondria and very scarce lysosome-mitochondrial complexes, suggestive of mitophagy inhibition. However, PGAM5\textsuperscript{CKO} cardiomyocytes contained elongated mitochondria and a preserved mitochondrial network, showing also little interaction with lysosomal vesicles (Fig. 7E–F). Meanwhile, we found in addition that the myocardial expression of the autophagy/mitophagy markers (LC3II/II and p62) was altered by I/R injury but not by PGAM5 deletion (Fig. 7G–I). Therefore, although PGAM5 was first revealed as a contributor to hypoxia-induced mitophagy through the dephosphorylation of Fundc1, our data indicates that PGAM5 levels do not influence post-I/R mitophagic activity in mouse cardiomyocytes.

4. Discussion

This study employed cardiac-specific PGAM5 knockout mice to explore the role of PGAM5 in cardiac I/R injury. Our results illustrate that: (1) PGAM5 transcription and expression are upregulated at the stage of reperfusion; (2) I/R-mediated PGAM5 upregulation promotes necroptosis rather than apoptosis in cardiomyocytes; (3) cardiac-specific deletion of PGAM5 attenuates I/R-mediated necroptosis but not apoptosis; (4) PGAM deletion rescues deficits in mitochondrial homeostasis induced by I/R by increasing mtDNA copy number and transcript levels, improving respiratory capacity, and decreasing mtROS production; (5) I/R promotes mitochondrial fission through the induction of Drp1\textsuperscript{S616} phosphorylation and Drp1\textsuperscript{S637} dephosphorylation; PGAM5 deficiency interrupts Drp1\textsuperscript{S637} dephosphorylation but has no impact on I/R-mediated Drp1\textsuperscript{S616} phosphorylation, partially attenuating mitochondrial division; (6) mitochondrial fusion, which is inhibited by I/R injury, might be stimulated by PGAM5 deletion; (7) I/R suppresses mitophagy through the upregulation of CK2, whereas PGAM5 deletion fails to rescue this effect; (8) mitophagy-related cell death was not apparent in the reperfused myocardium; instead, mitophagy activation prevents necroptosis and apoptosis in cardiomyocytes exposed to sI/R injury. These data highlight that PGAM5 determines pathology in cardiac I/R injury through the induction of necroptosis rather than apoptosis. Mechanistically, PGAM5 blunts mitochondrial bioenergetics, triggers mitochondrial oxidative stress, partially induces mitochondrial dynamics disorder, and has no effect on mitophagy in the reperfused heart. Taken together, utilizing cardiac-specific conditional PGAM5 knockout assays and adenovirus-mediated gene overexpression experiments, we describe the precise role of PGAM5 in sensitizing cardiomyocytes to necroptosis through the perturbation of mitochondrial quality control.

PGAM5 is a mitochondrial outer-membrane serine/threonine-protein phosphatase first discovered as a Keap1 substrate in eukaryotic cells [64]. Oxidative stress inhibits Keap1-mediated ubiquitination and degradation of PGAM5, suggesting a link between PGAM5 and cellular adaptive responses [57]. In addition, although data from mammalian cells is lacking, the interaction between PGAM5 and apoptosis signal-regulated kinase 1 (ASK1), one of the MAPK kinases accounting for apoptosis induction through the activation of the MAPK-JNK and MAPK-p38 signaling pathways, has been reported in Drosophila and Caenorhabditis elegans \[65,66\]. Interestingly, a recent study reports that PGAM5 is able to dephosphorylate BCL-xL at Ser62, thus reversing Bcl-xl sequestration of BAX/BAK and conferring resistance to apoptosis [67]. Moreover, PGAM5 has been shown to function as a predominant mediator of TNFα-activated necroptosis and a driver of inflammatory processes through the induction of mitochondrial fission [14,68]. Such a scenario is supported by recent studies that specifically delineate the mechanisms whereby PGAM5 contributes to inflammation-related necroptosis in the liver \[69,70\] and during acute pancreatitis [71]. Intriguingly, studies addressing the role of PGAM5 in cardiac I/R injury have yielded conflicting results, as both necroptosis stimulation \[15\] and inhibition \[16\] have been described in I/R-exposed rat and mouse hearts, respectively, upon PGAM5 inhibition or knockout. Nevertheless, there were clear methodological differences between these studies; whereas in the rat study 1 h/3 h I/R injury was performed in vivo after systemic pharmacological PGAM5 inhibition \[15\], in the mouse study isolated hearts from PGAM5-KO and PGAM5-WT mice were exposed to a 25 min/90 min I/R protocol ex vivo \[16\]. Conceivably, these seemingly contradictory results may be reconciled if PGAM actions were determined by the degree and duration of the ischemic challenge; under this hypothesis, PGAM activity would protect cells from hypoxic cell damage by activating mitophagy early after an ischemic insult, and mediate instead necroptosis once mitophagy becomes ineffective or is suppressed at the stage of reperfusion. Our data using PGAM5\textsuperscript{CKO} mice provide strong evidence that necroptosis rather than apoptosis or mitophagy-mediated death is driven by PGAM5 in cardiac I/R injury. These interlinked mechanisms between PGAM5 and necroptosis could offer new targets to prevent cardiomyocyte death.

I/R-mediated cardiomyocyte death is associated with mitochondrial dysfunction. Research has shown that oxidative stress, abnormal mitochondrial division, defective mitochondrial fusion, and dysregulated mitophagy may act synergistically to trigger cardiomyocyte death through pleiotropic effects \[72,73\]. We found that I/R failed to induce mitochondrial fragmentation in PGAM5-depleted cardiomyocytes, an effect linked to blunted PGAM5-mediated Drp1 dephosphorylation. Drp1 possesses two critical phosphorylation sites, which in turn stimulate (Drp1\textsuperscript{S616} phosphorylation and Drp1\textsuperscript{S637} dephosphorylation; PGAM5 deficiency interrupts Drp1\textsuperscript{S637} dephosphorylation but has no impact on I/R-mediated Drp1\textsuperscript{S616} phosphorylation, partially attenuating mitochondrial division; (6) mitochondrial fusion, which is inhibited by I/R injury, might be stimulated by PGAM5 deletion; (7) I/R suppresses mitophagy through the upregulation of CK2, whereas PGAM5 deletion fails to rescue this effect; (8) mitophagy-related cell death was not apparent in the reperfused myocardium; instead, mitophagy activation prevents necroptosis and apoptosis in cardiomyocytes exposed to sI/R injury. These data highlight that PGAM5 determines pathology in cardiac I/R injury through the induction of necroptosis rather than apoptosis. Mechanistically, PGAM5 blunts mitochondrial bioenergetics, triggers mitochondrial oxidative stress, partially induces mitochondrial dynamics disorder, and has no effect on mitophagy in the reperfused heart. Taken together, utilizing cardiac-specific conditional PGAM5 knockout assays and adenovirus-mediated gene overexpression experiments, we describe the precise role of PGAM5 in sensitizing cardiomyocytes to necroptosis through the perturbation of mitochondrial quality control.

PGAM5 is a mitochondrial outer-membrane serine/threonine-protein phosphatase first discovered as a Keap1 substrate in eukaryotic cells [64]. Oxidative stress inhibits Keap1-mediated ubiquitination and degradation of PGAM5, suggesting a link between PGAM5 and cellular adaptive responses [57]. In addition, although data from mammalian cells is lacking, the interaction between PGAM5 and apoptosis signal-regulated kinase 1 (ASK1), one of the MAPK kinases accounting for apoptosis induction through the activation of the MAPK-JNK and MAPK-p38 signaling pathways, has been reported in Drosophila and Caenorhabditis elegans [65,66]. Interestingly, a recent study reports that PGAM5 is able to dephosphorylate BCL-xL at Ser62, thus reversing Bcl-xl sequestration of BAX/BAK and conferring resistance to apoptosis [67]. Moreover, PGAM5 has been shown to function as a predominant mediator of TNFα-activated necroptosis and a driver of inflammatory processes through the induction of mitochondrial fission [14,68]. Such a scenario is supported by recent studies that specifically delineate the mechanisms whereby PGAM5 contributes to inflammation-related necroptosis in the liver [69,70] and during acute pancreatitis [71]. Intriguingly, studies addressing the role of PGAM5 in cardiac I/R injury have yielded conflicting results, as both necroptosis stimulation [15] and inhibition [16] have been described in I/R-exposed rat and mouse hearts, respectively, upon PGAM5 inhibition or knockout. Nevertheless, there were clear methodological differences between these studies; whereas in the rat study 1 h/3 h I/R injury was performed in vivo after systemic pharmacological PGAM5 inhibition [15], in the mouse study isolated hearts from PGAM5-KO and PGAM5-WT mice were exposed to a 25 min/90 min I/R protocol ex vivo [16]. Conceivably, these seemingly contradictory results may be reconciled if PGAM actions were determined by the degree and duration of the ischemic challenge; under this hypothesis, PGAM activity would protect cells from hypoxic cell damage by activating mitophagy early after an ischemic insult, and mediate instead necroptosis once mitophagy becomes ineffective or is suppressed at the stage of reperfusion. Our data using PGAM5\textsuperscript{CKO} mice provide strong evidence that necroptosis rather than apoptosis or mitophagy-mediated death is driven by PGAM5 in cardiac I/R injury. These interlinked mechanisms between PGAM5 and necroptosis could offer new targets to prevent cardiomyocyte death.
Redox Biology 38 (2021) 101777

our experimental settings. Previous studies demonstrated that Fundc1, a mitophagy inducer, can be inactivated by CK2-mediated phosphorylation at Ser13, but is then reactivated by PGAM5-mediated dephosphorylation under hypoxic stimulation [60]. However, abundant phosphorylated Fundc1[13] was noted in the reperfused heart regardless of PGAM5 deletion. Interestingly, in CK2-depleted cardiomyocytes, PGAM5 expression is correlated with dephosphorylated Fundc1[13] levels. This suggests that CK2 plays a prominent role in managing cardiomyocyte mitophagy, whereas PGAM5 may play a compensatory role once CK2 action on Fundc1 is inhibited or lost. This finding is in accordance with our previous study indicating that reperfusion-mediated mitophagy depression is attributable to CK2 upregulation [24]. Along these lines, we excluded the existence of mitophagy-related death in the reperfused heart and confirmed through in vivo treatment with the mitophagy activator uronil A that mitophagy activation protects cardiomyocytes from I/R-induced death.

In conclusion, our results indicate that PGAM5 upregulation facilitates necroptosis during myocardial I/R injury by impairing mitochondrial quality control mechanisms. These findings lay the foundation for future research addressing the connection between PGAM5, mitochondrial quality surveillance, and cardiomyocyte survival in the context of I/R and suggest the therapeutic potential of modulating cardiac PGAM5 levels in coronary reperfusion surgery patients.

Declaration of competing interest

The authors have declared that they have no conflicts of interest.

Acknowledgements

None.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.redox.2020.101777.

Funding

This study was supported by grants from the National Natural Science Foundation of China (No. 81900252, 81870249, 82000537). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author contributions

HZ, YT, and ST were involved in the conception and design of the study, performance of experiments, data analysis and interpretation, and manuscript writing; HZ and DM were involved in development of study, performance of experiments, data analysis and interpretation, and manuscript writing; FT and HZ obtained financial support, supervised the study and approved the final manuscript.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

References

[1] E. Murphy, C. Stiebenberg, Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury, J. Am. Coll. Cardiol. 63 (14) (2014) 1454-1471.
[2] S.M. Davidson, P. Ferdinandy, I. Andreadou, H.E. Botker, G. Heusch, B. Ibanez, J. Sarhan, B.C. Liu, H.I. Muendlein, C.G. Weindel, I. Smirnova, A.Y. Tang, K.A. Davies, M.C. Tanzer, M.D.W. Griffin, Y.F. Mok, S.N. Young, R. Qin, E.J. Petrie, J. Martinez, E.H. Kim, S.W. Wong, J. Martinez, Programmed Necrosis and Disease: We interrupt the review topic of the week, J. Am. Coll. Cardiol. 73 (1) (2019) 89-109.
[3] B. Ibanez, G. Heusch, M. Ovize, F. Van De Werf, Evolving therapies for myocardial ischemia/reperfusion injury, J. Am. Coll. Cardiol. 65 (14) (2015) 1454-1471.
[4] D.J. Haaseleyen, D.M. Yellon, Myocardial ischemia/reperfusion injury: a neglected therapeutic target, J. Clin. Invest. 123 (1) (2013) 92-100.
[5] P. Zhu, S. Hu, Q. Jin, L. Li, P. Tian, S. Toan, Y. Li, H. Zhuo, Y. Chen, Ripk3 promotes ER stress-induced necroptosis in cardiac IR injury: a mechanism involving calcium overload/XO/ROS/mPTP pathway, Redox. Biol. 16 (2018) 157-168.
[6] H. Zou, D. Li, P. Zhu, Q. Ma, S. Toan, J. Wang, S. Hu, Y. Chen, Z. Zhang, Inhibitory effect of melatonin on necroptosis via repressing the Ripk3-PGAM5-Cyp5-mPTP pathway attenuates cardiac microvascular ischemia-reperfusion injury, J. Pineal Res. 63 (5) (2018), e12503.
[7] T. Zhang, Y. Zhang, M. Cui, L. Jin, Y. Wang, F. Li, Y. Liu, W. Zheng, H. Shang, J. Zhang, M. Zhang, H. Wu, J. Guo, X. Zhang, X. Hu, C.M. Cao, R.P. Xiao, CaMKII is a RIP3 substrate and mediates mitophagy and intercellular stress-induced myocardial necrosis, Nat. Med. 22 (2) (2016) 175-182.
[8] M.I. Orelmanns, S. Koudstaal, S.A. Chaumeulle, D.P. De Kleijn, P.A. Doevendans, J. P. Sluijter, Targeting cell death in the reperfused heart: pharmacological approaches for cardioprotection, Int. J. Cardiol. 165 (3) (2013) 410-422.
[9] D. Frank, J.E. Vincy, Pyroptosis versus necroptosis: similarities, differences, and crosstalk, Cell Death Differ. 26 (1) (2019) 99-114.
[10] E.H. Kim, S.W. Wong, J. Martinez, Programmed Necrosis and Disease: We interrupt your regular programming to bring you necroinflammation, Cell Death Differ. 26 (1) (2019) 25-40.
[11] J. Sarhan, B.C. Liu, H.I. Muendlein, C.G. Weindel, I. Smirnova, A.Y. Tang, K.A. Davies, M.C. Tanzer, M.D.W. Griffin, Y.F. Mok, S.N. Young, R. Qin, E.J. Petrie, J. Martinez, Programmed Necrosis and Disease: We interrupt the review topic of the week, J. Am. Coll. Cardiol. 73 (1) (2019) 89-109.
[12] K.A. Davies, M.C. Tanzer, M.D.W. Griffin, Y.F. Mok, S.N. Young, R. Qin, E.J. Petrie, J. Martinez, Programmed Necrosis and Disease: We interrupt the review topic of the week, J. Am. Coll. Cardiol. 73 (1) (2019) 89-109.
[13] H. Zhou, C. Shi, S. Hu, H. Zhu, J. Ren, Y. Chen, BI1 is associated with microvascular ischemia-reperfusion injury via improving mitochondrial fusion/ mitochondrial fission by CK2alpha, Basic Res. Cardiol. 113 (4) (2018) 23.
[14] H. Zhou, J. Wang, P. Zhu, H. Zou, S. Hu, J. Ren, Y. Chen, NRIAA1 aggravates the cardiac microvascular ischemia reperfusion injury through suppressing FUNDCl-mediated mitophagy and promoting MFI-required mitochondrial fission by CXaPA, Basic Res. Cardiol. 113 (4) (2018) 23.
[15] Y. Zhang, Y. Jiang, J. Zhang, M. Zhang, H. Wu, J. Guo, X. Zhang, X. Hu, C.M. Cao, R.P. Xiao, CaMKII is a RIP3 substrate and mediates mitophagy and intercellular stress-induced myocardial necrosis, Nat. Med. 22 (2) (2016) 175-182.
[16] H. Zhou, S. Toan, P. Zhu, J. Wang, J. Ren, Y. Chen, DNA-PKcs promotes cardiac ischemia reperfusion injury through mitigating BI1-governed mitochondrial homeostasis, Basic Res. Cardiol. 115 (2) (2020) 11.
[17] P. Akbari, E.J.M. Huijbers, M. Themeli, A.W. Griffin, J.R. Van Beinum, The tumor vasculature an attractive CAR T cell target in solid tumors, Angiogenesis 22 (3) (2019) 383-395.
[18] A. Florido, N. Sarasie, C. Cornebirne, M. Almeida, M. Parsons, I. Baticin-Handeler, J. P. Fernandez, J.G. Costa, G. Garranz, M. Castro, N.G. Oliveira, A.S. Fernandez, The manganese(III) porphyrin MnTetrAll2-P2Pys(−) modulates intracellular ROS and breast cancer cell migration: impact on doxorubicin-treated cells, Redox. Biol. 20 (2019) 367-378.
[19] L. Cappello, M.A. Bayar, L. Albige, G. Le Teuff, B. Escudier, A new prognostic model for survival in second line for metastatic renal cell carcinoma: development and external validation, Angiogenesis 22 (3) (2019) 383-395.
[29] B. Galjart, P.M.H. Nierop, E.P. Van Der Plaats, R. Van Den Brink, D.J. Hoppener, S. Daelemans, L.Y. Dixir, C. Verhoef, P.B. Vermeulen, D.J. Grünhagen, Angiogenic demophsit cathedrical growth pattern as a prognostic marker of good outcome in patients with colorectal liver metastases, Angiogenesis 22 (2) (2019) 355–368.

[30] K.A. Mapuskar, H. Wen, D.G. Holanda, P. Rastogi, E. Steinrich, R. Han, M. C. Coleman, M. Attanasio, D.P. Riley, D.R. Sipity, B.G. Allen, D. Zepeda-Orozco, Persistent increase in mitochondrial superoxide mediates cisplatin-induced chronic kidney disease, Redox. Biol. 20 (2019) 98–106.

[31] J. Mo, B. Enkjarl, Z.D. Travis, K. Zhou, P. Wu, G. Zhang, Q. Zhu, T. Zhang, J. Feng, W. Xu, U. Okah, S. Chen, J. Tang, J. Zhang, J.H. AVEE attenuates oxidative stress and neuronal apoptosis via Max/PAK/CR/ECR/UCP-2 pathway after subarachnoid hemorrhage in rats, Redox. Biol. 20 (2019) 75–86.

[32] M.S. Narzt, I.M. Nagelreiter, O. Oskolkova, V.N. Bochkov, J. Latreille, M. Fedorova, Y.R. Kim, J.I. Baek, S.H. Kim, M.A. Kim, B. Lee, N. Ryu, K.H. Kim, D.G. Choi, H. Ito, Mitochondrial protein S-thiolation in Gram-positive bacteria, Redox. Biol. 20 (2019) 130–145.

[33] H. Zhou, P. Zhu, J. Guo, N. Hu, S. Wang, D. Li, S. Hu, J. Ren, F. Cao, Y. Chen, Ripk3 induces mitochondrial apoptosis via inhibition of FUNDC1 mitophagy in cardiac IR injury, Redox. Biol. 13 (2017) 498–507.

[34] W. Feng, H. Geng, Y. Wang, G. Zhu, T. Xue, Y. Wang, G. Cui, circFTRF8 functions as a ceRNA of miR-1236-3p to promote colorectal cancer progression, Mol. Ther. Nucleic Acids 18 (2019) 375–387.

[35] H. Zhou, S. Hu, Q. Jin, C. Shi, Y. Zhang, P. Ma, F. Tian, Y. Chen, Mff-dependent mitochondrial fission contributes to the pathogenesis of cardiac microvascularature ischemia/reperfusion injury via induction of mROS-mediated cardiopulmonary oxidative stress and HK2/VDAC1 disassociation-involved MPT opening, J. Am. Heart Assoc. 6 (3) (2017).

[36] A.J. Kowalowski, Strategies to detect mitochondrial oxidents, Redox. Biol. 21 (2019), 101069.

[37] H. Zhou, P. Zhu, J. Guo, N. Hu, S. Wang, D. Li, S. Hu, J. Ren, F. Cao, Y. Chen, Ripk3 induces mitochondrial apoptosis via inhibition of FUNDC1 mitophagy in cardiac IR injury, Redox. Biol. 13 (2017) 498–507.

[38] Y.R. Kim, J.I. Back, S.H. Kim, M.A. Kim, B. Lee, N. Ryu, K.H. Kim, D.G. Choi, H. Ito, Mitochondrial protein S-thiolation in Gram-positive bacteria, Redox. Biol. 20 (2019) 98–106.

[39] H. Zhou, P. Zhu, J. Guo, N. Hu, S. Wang, D. Li, S. Hu, J. Ren, F. Cao, Y. Chen, Ripk3 induces mitochondrial apoptosis via inhibition of FUNDC1 mitophagy in cardiac IR injury, Redox. Biol. 13 (2017) 498–507.

[40] Y.R. Kim, J.I. Back, S.H. Kim, M.A. Kim, B. Lee, N. Ryu, K.H. Kim, D.G. Choi, H. Ito, Mitochondrial protein S-thiolation in Gram-positive bacteria, Redox. Biol. 20 (2019) 98–106.

[41] Y. Guo, Y. Nong, D.N. Takuye, G. Rokosh, J. Du, X. Zhu, M. Book, A. TOMLIN, Q. Li, R. Bolli, Inducible cardiac-specific overexpression of cyclooxygenase-2 (COX-2) confers resistance to ischemia/reperfusion injury, basic Res. Cardiol. 114 (5) (2019) 32.

[42] D.C. Fuhrmann, I. Wittig, B. Brune, TMEM126B deficiency reduces mitochondrial ROS oxidation by ITP, attenuating HIF-1alpha stabilization and IL-1beta expression, Redox. Biol. 20 (2019) 204–216.

[43] H. Zhou, P. Zhu, J. Guo, N. Hu, S. Wang, D. Li, S. Hu, J. Ren, F. Cao, Y. Chen, Ripk3 induces mitochondrial apoptosis via inhibition of FUNDC1 mitophagy in cardiac IR injury, Redox. Biol. 13 (2017) 498–507.

[44] T.M. Stepkowski, M.K. Kurszewski, Molecular cross-talk between the NRF2/KEAP1 pathway and the Keap1-dependent ubiquitin ligase complex, J. Biol. Chem. 281 (2006) 387.

[45] T. Martens, M. Rivard, R. Foresti, HYCO-3, a dual CO-releaser/Nrf2 activator, cells, Redox. Biol. 27 (2019), 101075.

[46] J. Hausenloy, Mitochondria in acute myocardial infarction and cardioprotection, Trends Biochem. Sci. 45 (7) (2020) 564–577.

[47] S.C. Lo, M. Hannink, PGAM5, a Bel-1X-interacting protein, is a novel substrate for the redox-regulated Keap1-dependent ubiquitin ligase complex, J. Biol. Chem. 281 (2006) 387.

[48] K. Takeda, Y. Komuro, T. Hayakawa, H. Oguchi, Y. Ishida, S. Muramaki, T. Nouguchi, H. Koshita, Y. Sekine, S. Iemura, T. Natsumi, H. Ichijo, Mitochondrial phosphoglycerate mutase 5 uses alternate catalytic activity as a protein serine/threonine phosphatase to activate AKT1, Proc. Natl. Acad. Sci. U. S. A. 106 (30) (2009) 12301–12305.

[49] T. Kamata, Z. Zhang, R. Chang, H. Cheng, M. Yu, T. Zhao, J. Luo, K. Tanabe, H. Tanaka, S. Seo, K. Taura, K. Machida, N. Takeda, S. Saji, S. Uemoto, M. Asagiri, Necrostatin-1 protects against reactive oxygen species (ROS)-induced hepatotoxicity in acetaminophen-induced acute liver failure, FEBS Open Bio 4 (2014) 777.

[50] R. Mukherjee, O.A. Mareninova, Y.V. Odinkova, W. Huang, J. Murphy, M. Chovanov, M.A. Javed, L. Men, D.M. Booth, M.C. Cane, M. Awais, B. Gavillet, R. M. Pruss, S. Schaller, J.D. Molkentin, A.V. Tepikin, O.H. Petersen, S.J. Pandol, I. Gulovskiy, D.N. Cridale, A.S. Gulovskaya, R. Sutton, N.P.B. Unit, Mechanism of mitochondrial permeability transition pore induction and damage in the pancreas: inhibition prevents acute pancreatitis by protecting production of ATP, Gut 65 (8) (2016) 1336–1346.

[51] C.J.A. Ramachandran, S. Hernandez-Rosendez, G.E. Crespo-Avila, Y.H. Lin, D. H. Hendry, Mitochondria in acute myocardial infarction and cardioprotection, ElBioMedicine 57 (2020), 102884.

[52] A.V. Pozynak, E.A. Ivanova, L.A. Sobeni, S.F. Yet, A.N. Erekhov, The role of mitochondria in cardiovascular diseases, Biology 9 (6) (2020).

[53] G.W. Dorn, Evolving concepts of mitochondrial dynamics, 2nd, Annu. Rev. Physiol. 81 (2019) 1–17.